MA
AXSM icon

MYDA Advisors’s Axsome Therapeutics AXSM Stock Holding History

MYDA Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-6,000
Closed -$494K – 111
2020
Q2 		$494K Buy
+6,000
New +$462K 0.3% 66
2019
Q4 		– Sell
-3,409
Closed -$69K – 111
2019
Q3 		$69K Buy
+3,409
New +$87.6K 0.03% 104

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MYDA Advisors's AXSM Position: Q3 2020 in Review

MYDA Advisors sold out of Axsome Therapeutics (AXSM) in Q3 2020, closing a stake of 6,000 shares — an estimated $494K sold.

MYDA Advisors first reported a position in AXSM in Q3 2019 and held it in 2 quarters. The position peaked at $494K in Q2 2020. 174 funds tracked by Wall St. Rank hold AXSM as of Q3 2020.

  • MYDA Advisors reported no remaining Axsome Therapeutics position as of Q3 2020 after selling out during the quarter.
  • MYDA Advisors sold 6,000 Axsome Therapeutics shares in Q3 2020, an estimated $494K.
  • MYDA Advisors first reported a position in Axsome Therapeutics in Q3 2019 and held it in 2 quarters.
  • MYDA Advisors's Axsome Therapeutics position peaked at $494K in Q2 2020.
  • 174 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2020.

Based on MYDA Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.